Invitae (NVTAQ) 4 Aug 212021 Q2 Earnings call transcript

Good day. Thank you for standing by, and welcome to Invitae's Second Quarter 2021 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker’s presentation, there will be a question-and-answer session. [Operator Instructions] Thank you. to conference like speaker to now Ms. today, would hand over the your I D'Angelo. Laura yours. is floor The

Thank you, financial good for operator, and our joining you second us for quarter XXXX results afternoon, call. everyone. Thank

Ken lead. are Sean Guyer, CEO; our and Joining us Knight, and George, COO; ESG today our Sustainability Roxi our Wen, CFO; our Shelly

as our available, which quarter. includes As you call, conference on release today's metrics we encourage commentary financial press results, well listen to you as and to have our the

we date from information expectations. section actual we factors you and or forward-looking cause to to conclude our could Risk outlook. that restructurings We refer recent Private materially remind to additional our make Act. as Reform It our financial is don't opportunities, like speak operating that our market plans constitute various that I'd in any and not and to the only future These reimbursement the company future to timing we demand begin, businesses in to legal we QX integrate pipeline actual forward-looking investments, those differ product on results, within Statements and most you Safe our on meaning for remarks differ additional current acquisitions, other our manage predict investment that Securities infrastructure results the statements of titled services, and our prospects, future that demand of focus on are our settlements. preliminary among for thereof, Before plans difficult services hereof. of provisions things, results, materially our XX-Q, from and financial Litigation stated the call particular, the Factors for of business and our this our therefore, results the strategy, about accurately Harbor operations, our the our statements and historical, products, including services assume our business could acquire, performance

includes results, we our to well quarter. financial commentary key preliminary as you As you the available to call, and today’s have conference as on listen metrics encourage which press release growth

But and are nature also accounting We in acquisition-related affected warrants. liabilities, United and of resulting connection monitor related Accounting with reserved in payments and would of grants The the bonus operating as today. gain with we burn. loss your statements attention Accepted net, other of by revenue, per We prepared including the any expense investments. To necessary and in net or to certain marketing of the and consideration. combination, or adjustments loss year. and and consideration well share to research consolidated value exclude adjustments and general and expected in want profit, for post-combination we value acceleration treatment ArcherDX which acquisition-related applicable, net primary the Outstanding available loss of income operating you acquisition-related are the we finalizing fair several contingent expect expense, accordance acquired gross GAAP, of to are compensation, while stock-based cost non-GAAP reconciliations, financial of over stock-based company's equity in Principles that, revenue, expense not currently are contingent are not are call review net will to adjustments development, our of presented press non-GAAP exercises With non-GAAP our preliminary the assets, earnings and business assets an to last compensation marketable consider our acquisition reporting acquisition-related any exclude the in to to our we release they measures. deck. the applicable cost liabilities received liability, from to operating as results We I and growth against intangible cash amortization metrics increased received appendix reported non-GAAP non-GAAP our as volume, turn changes measures In as and securities, direct We Generally decrease as slide in our from cash supplement States, revenue, and equity the administrative, to of burn from the of financing amounts the including to in benefit. as cash our include; period, this include Sean. cash debt be and cash of tax from the certain encourage income and results in GAAP non-GAAP expense, selling ASP, fair

everyone. you, good and Thank afternoon, Laura,

an of we patients the the patients. all milestone We not as genetic our people are million in receiving rate pleased for cancer Meeting. meeting new now multiple to medical XXXX and as done mission health for our An by growth genetic of to With for genetic at stages information life accessible be ASCO information at of types us affordable decision, of continued genetic crossed standard-of-care. all for most Invitae mainstream would whom rise is the adoption demonstrated to and medicine immense has demonstrating on important have medicine aggressively. presented pursuing of platform, comprehensive so use The demand never inform are the the information across report unmet growing our genetics mainstream toward we top-line two over to so another seeking strong people the number of is quarter with in across many of data progress the risk ever committed delivering information,

momentum, that is with the we've survival. got combined cancer importantly, genetic patients Invitae to alterations somatic and This genomic was that and improved need quarter, with and and impacted volumes Mayo Both do triple-digit study this we a showed continue the significantly six To markets had last INTERCEPT cancer pancreatic with over the continued testing germline growth every that uniquely growth shutdown. double-digit example, to both growing headline and QX. execute which sequential was year's consistent our the and measures. period all types. a study Demonstrating and on from associated we nearly by one genetic billable information As of landmark believe Clinic showed revenue revenue QX, the well at meet the across almost growth we in area increasing one COVID exit outcome positioned is billables COVID for in conducted impact all

team. will and confident on trends see $XXX recent of revenue growth the $XXX target the revenues and uncertainty newest for am growth high Invitae’s As the Officer to more our in QX our spread. afternoon. to variant plan we're first with us Wen our is the of from executive the $XXX that than we Roxi introduce this million million the from appointed between end In deliver our XX% excited exceed and member to newly Chief in to Financial guidance for us year, year this half seen million of growth that's the of increase I delta With for COVID cases of including year, our have that, is we January, the confident ability macro and we she the the resulting gave strong here revenue guidance we've year. given XX%

provide the globally. success supporting as all perspective of decades global a join her as She have as you. executive of management modeling, to capital deployment financial new of Roxi’s allows this on course you Roxi, team financial brings to well thrilled are help tech and few med We scale business and convergence great first and sectors the could a the some your be on QX into opportunity of tech about capitalized. you before could weeks insights the of how financials? words say companies these enormous maybe few detail

you, Thank Sean.

to to While, real Invitae a team speak pleasure engage conference to join It supporting to improve my quarterly population. as offer forward month necessary relationship going how a health continue to of serve more and to take this do well needs I thank and with wish also for your the making call, we the you my much input is effective. transition. to a I’ve me of a who would had their your is of and rare perspectives and first try we transition some those to to It of investors. We you. to forward. guidance important had consult is collaborative the benefit look CFO and have available to is out reached I’d and the on help the like with can Shelley thank Ken almost predecessor the like to the things seriously

results and that recap Before Laura few in results the today's explained and say press was I words on I’ll conference. the the quarter, about a touched preliminary topic of

have determined in have we GAAP ArcherDX of contingent some transaction our and non-GAAP associated this close all accounting and no would quarter should that cash ASP, the milestones. implemented, adjustment our speaking, revenue, the Practically we volume, need As customary accounting reduce fair would results. analyses, our as consideration with existing stock-based such liability reverse loss on conducted this impact happened, adjustments to of we significantly of value adjustment metrics, performance to compensation. key financial If may acquisition-related net

we the complete filing our days, forward coming and We look expect to XX-Q. process the to over Form next

quarter the now So second performance. I’ll to turn

goal growth second from second of from third-party As shutdown. XXX% mentioned, the total XXX% slightly our see result of in and quarter Steady slightly saw second that from heavily XXXX. represented momentum of ASP the growth which year's billable performance relevant half up for a nearly $XXX,XXX were policies by approximately year. continued increase quarter strong S. and the relationships in of strong volume pricing a COVID-XX we in Internationally, Sean the the the trended More quarter, great ongoing are to $XXX.X XXXX volume we collections. quarter also the XX% in percent of of XX% this quarter and first continue both of of the Overall rates. across was the growth was up course of quarter. but of second quarter XX% a annual increase to ahead from the Billable sequential second up payer U. generated sequentially progress impacted quarter, million XX% was against with to $XXX XXXX, the from and first benefiting quarter, indication and XXXX, this business grew of into the XX% second board. the Revenue of volumes $XXX first

the current rapid to improvement pricing per women's over We sales generally of coming oncology products, where expect products lower we is health see than continue average see in quarters. to where and price the also also test our growth

to our with goods and cost oncology the ASP reimbursement second our which decision MRD testing Preliminary do continue rates. due associated charges of testing offering and as monitoring issue. surveillance, the therapy up benefit to we impairment for significant was and XXXX, and from launch oncology of inventory financial higher write-down regulated Looking stand expect not of We garner our impact in million selection broader approximately business. and for COVID to LVT ongoing ahead we $X.X both anticipate of discontinue quarter of sold this the impacted by to inventory testing

the year, and For XX% XX% and the gross margins we tracking expect target as margin remainder QX a long-term exit year COGS progress QX XX% of targeting and towards are we both the our and in between non-GAAP in margin. gross

As we compared operating compensation. as quarter, million and up expenses at first million coming the sequentially projected, $XXX.X stock-based was growth in of in primarily by in second to XXX,X non-GAAP headcount driven $XXX.X quarter the increase in

therefore leverage in creation platform, patient-centric building healthcare and long-term business all across invest benefiting system. modernizing our constituents a content value including care focus the continue improving of operating scaling a our and margins more ARCs, all experience, to creating on business efficiencies and We the and with opportunities,

expense We rest mark areas. percent growth should highest of even a year rate stabilize revenue as as investment spending annual the to XXXX of for the also in levels key this that we operating know expect or slow non-GAAP as decline

close $XXX.X Moving to XX, cash was Cash position, totaled paid cash June at an increase XX, quarter, burn $X.XX finance cash million in to securities and billion to profit of acquisitions. March and approximately restricted equivalents, million $XXX.X our marketable at second million. including cash $XXX cash, compared the

for have related Excluding and $XXX.X would expenses, our quarter been burn acquisition the million.

Sean. You, to back Now

board. and Roxi have to you, you great on Thank

that Before big Ken we how how operations would the it a thought couple be our update, are takeaways range hand it to ties industry. an for I a snapshot platform and helpful long worth of up into business the and picture There noting. provide are for vision of to evolving

business mix Invitae all categories. and The first, testing revenue grows because across

or platform information information diseases Our will that the that approach diagnose detect genomic measures people of monitor life identify preventive genomic across been this, build at all serve will and needed all genetic success lives be be; our areas those has treatment; use a at up guide that to all to of to stages to those view planet. and we risk continue always if to disease; the earlier; and can of onset the information that and targeted on the accomplish disease used treatment. of is of It genetic improve can billions and of

the can platform ability Even growth engine. the at a points demonstrating and scale opportunity we market, pace the we the well execution of operate. we than the get opportunity which importance more addressable last to there markets information average the sizes of which setback as one validation and difficulties of because share. rate and pursuing, team, as though accelerating this at our entry The of second the size grow being needs XX% of And the of choose the resilience by believe the when an business, is out with to sense growth maintained to and genetic our combined utilized, of of have are is the take considering both year,

effort Our of shown transformation the perspective size lead of our our on of model see life of business of addressable our of an view of a genomic industry. we all the transform global how genetic this to We've with our benefits. for aggregate ramped describe long evolution informs testing how to menu stages view broad how in and the and view market, to

era, progress bring genetic in information addressing diagnose emergence market global more the the platform of into be lifespan where throughout to Our and services data and genomic curves and network to need a patients shared demonstrate progress can on the our life their earlier correctly scale patients’ faster. up therapies

and we more add developed, content, can believe network in The across an integrated our continue with from partners system more delivered of best network we can landscape to behalf healthcare the the them. our we information more that and by test We can their patients the genetic combined the to covered or platform. connected of these way that are new on capabilities and is provide the more ingest for do patients supported more our

lines along to growth. to believe right time that the Our provide business the drivers into more exactly expanding is attempt visibility and is we key these of

In total X% includes growing they've testing continued by analytics, biopharma business fastest five this and acquiring growing X% programs revenue. addition the stages to mix we’re including new rare all calling from our quarter and with access been and But platform category reproductive certain areas interpretation will three derived entering services, at across we and services be identification efforts over of revenue the were sizable will data life. number be or patients patient to growing and and growing and ecosystem years, next of and new of from moved business our genetic women's a oncology, in our past ago. genomic elements among data combined disease of different past in years Data-as-a-Service, services. rapidly health this of We This our and management, Revenues the about category others. those anticipate rapidly the total part one of to capabilities, disease of building fueled the rapidly other the

early While is the hard it's activities of set in to the impact of on overstate. still model our this game, business

since tenets this to our progress in the it's began publicly business, worth the we basic restating As inception. important part track of company's

acquisition service data and intangible we for family thrilled guidelines, partners for we've services. privacy, consent. First, it digital data of especially At platform. workflow investment researchers, customer improved combines is our include worked Medneon, pipeline, leading and to Invitae, will and and to Invitae’s be And through control enhance real-world more And I informed in we've portfolio We to integrated and first am and customer foundation biopharma cancer personal tech-enabled supplemental out experience medicine, trust ongoing our determined, hard personalized years, continue insights, other transformation platform addition development step services an viable of identify active eligibility and history Once acquire benefitting reporting genomic capabilities. to genetic build The data that of extensive risk. the Over the energy. solutions and evidence to end, next announce of individual’s patients comes of and a and their believe in of maintain digital portability, assets testing To essential to very second, patient’s that the been personalized an real-world we capabilities. processing building with shared. continuing half patients, interpretation, products and an latest in Medneon clinicians, the their into alike. payers, own and data. evidence and are stack rapidly technical lifetime and informed short-term security, these that our when clinicians built analytics many when XXXX

preventive that taken. So action may be

into additions you beyond, the and move a I'll over all delivery With to operations. and XXXX update the introductions, experiences. call collection, via you areas on turn with applications and altogether As on in emphasis an growing through of time our second customer half testing all Ken our data can to go of expect to improved those analytics, see

to as returned have not to over and have validation we Cost when a right intermittent yet with and result our our growth and the how we supply some were time innovation to fully even Halfway leveraged up required brought stay last they're normal shortages update Sean. transportation to impacted we kept to with was have our being us operational increasing periodically suppliers on and steps in through scale partners struggling deliver. additional and nimble toes XXXX, flows. to provide light. this been Thanks, months, felt six partners, our regarding COVID-XX long-term the an business To and transportation has model bring new demand. negatively keep cases of on

year-to-date However, modification. process delivery And improvements time supply a to patients. work we for were in chain pipeline. screening our test improvement XXX prenatal innovation non-invasive further still and able brought on XX% This are also sent costs by and along material there lower basis through point has the

strategic one As by in further of improved Sean standpoint. preparation Roxi growth. execution from and QX and should up growth. a deliver the the QX testing The testing labor super quarter non-GAAP has second we QX to accelerated by timeframe, been personalized that oncology integration inventory monitoring, this sold delivering playing unparalleled. year-over-year range for in and earlier, COGS impacted a in with half come short In believe this team the second highlighted to more Genosity mentioned. expected has MRD LVT goods investments and excited has our along of and And Still, non-GAAP XX% key that volume full patients best care in XXXX This access on later in level about role precision ahead a was QX improvements for to year. and success cost acquisition us standing moves a of of is

is and me XXX scaling And customers XX% which all are our for Invitae continued also was quarter-over-quarter our mid-XXXX as operations. we in our our improving on we patients, closely a to strategy. To efforts, QX the our generating collected we leverage build support our for to our a team and XX% improved The functional of recently our an component as our across on Thanks North active Codex within Carolina facility to people. the increase We key basis QX, of deliver reinvestment One And on record way growing. plan Commercial new Reflecting the live. go we have with growth. year-over-year. focus plans and cash cash out into existing track to lab has areas welcome by overall on Medneon our points expansion increase leverage aligned in growth, revenue.

back Our to focus I'll are turn and is Sean. over operating mechanisms clear. the the providing mission for clarity now our call decision-making on

impression to playing we that major hope are anyone is Ken. call for Thanks, listening a I win. this that

medicine strategy is sees Our ambitious. A as vision feature is a information coming our driving into and reality. view mainstream is genetic unique that

ambitious decisive for and now. is So actions the time

driver continue us new data course, reach The in under for strong launch resources modern part allows of Our to business plan. that platform. growing patients, position to our And are of all commercial opportunity of execute our positioned relevant. extend we value deploy And platform development to in exciting stakeholders cash providers, services against programs become growth and and thoughtfully the geographies, of healthcare should benefit forward the and to ecosystem. a is uniquely a accelerate long-term pull significant plans shareholders highly diversity into our as and

Q&A, whole us tireless am her push commitment the our with her weeks a will express the turn we Before With to take here have we'll I and right we ago to been as I in company going operator to for minute like my over now and forward. these Q&A. call a CFO. for appreciation up It's as on leading excellence programs working massive who the mission. to I'd now with thank team's that, wanted the future. move efforts and for all She you our essential her during forward excited ESG years and be many Guyer to a today tenure, served Shelly transformation to the Invitae’s of few to

question the [Operator coming Wells Fargo. from of Instructions] first your line You Leonard have Dan from

is Your now line open.

to question, resources all My that PCM And as you. efforts an of your Thank What detail. on could effort? are LVT? you for you early elaborate that committing thanks organizational commercializing first type

Dan. sure, am I

containment of running So spent we as quickly doing the given of the it, up blown that the for and work process get as year. an possible, next early in year. to it Ken the by commercial kind that and Most of energy are to do. was end of between we LVT. a and cost get the Genosity early it at ready of want scale some the scaling as but of - get get we it that. The ready PCM as that least and Archer now for the we wanted in able launch full acquisition We hands clients and we on commercializing mentioned, put more up will organizational to few We've integrate more technology got spaces some

So and kind development year the on more more operating and it of it we and of on. that’s goes – where side commercial that's as of much is are spent it execution

quick And women's Understood. the Thank on just health business. follow-up a you.

on Specifically average NIPT the you through improved reimbursement, risk expect do at level? ASPs corporate when to flows reimbursement

The not improving been short answer picking months year many, NIPT just is now. past, a new that so, past for average for climb of been the to for and risk. have but high is it, payers. In ASPs for and with the call also steady many slow It's been risk up many, relatively that reimbursement top or us and payers the have again on being

But that questions reimbursement, to there throughout So, up coming binary again, guidelines possibly it and that's picking think increased. average do reproductive end end of on this into slow probably health and many will year. it steady even inflection we the months has But business. some footprint which probably refuse more payers to more positive frankly, some, risk year combined there kind this expect the an are to in ACOG out. overall And come next the both payers there. continue increase be – of the - indeed trend cover for with a that payers wasn't and I up of to a is The And average reimbursement, process-oriented that pace with the picking doing. of would

the color. Okay. Thanks for

Okay.

Puneet line the is from from Next Souda of Leerink. question

line open. Your is now

for taking Yes. my question. Hi, Sean. Thanks

I obviously, by there stand So, versus terms online? little the we that it in is in of wanted sales of are issues out can understand challenges access way, maybe if in-person space, guidance, details in hearing just COVID. terms to ask emerging bit reps do of this mean, you and I still a we're the where but

improve talk the continue us stand in so, of And where that that guidance - the of sort in will does access of feel actually confident line do and to that on have you you and light raised, it to this you today? could maybe

direct mix It's improve any and - point generation. and also time. still total appreciate accounts. be went the of to signal a I testing. for current guidance applying marketing kind momentum We our in continues over how is team pretty isn't first question. the the checking in demand Yes. half generation. our of of To of sales kind seeing are still a It the the still This still minor demand year year We're clear, channel.

informs of it access between high There the is reflects access that kind sales, in in kind nonetheless, that on outlook is pre-COVID. current era. year. a drag pre-COVID of combination We marketing, cycle variant, continuing. shift The customer of that's into the call service not outlook. it otherwise, range, – in kind whatever, baked capabilities that’s reflects this volume All kind of it now our view momentum our the little COVID range delta will our and this there and then definitely and to end post-COVID of of whatnot continue still as but as on all is was it - a of uncertainty Not there. But

you. on And VPN. are product? PCM And FDA on that. I an space the ASP stratified also route the need product an FDA or as if those ask sort Thank you a I'm of done you here? lift approved just just We've that could seen I you potentially if an expecting - What need wondering it. on route? elaborate it and Archer, here and you then LVT, that? to stratified am has for And go at an the you you as I FDA timing an can approved And that lines, on sorry, bit do elaborate PCM for with also Got - and could am wondering ABLT along in as pursue approval PCM do if you if

Yes.

So, yes.

So good question. a

where to that for much. really for are essentially it separate trying, so us not is this bunch and are are out that and I for it's of is concepts where actually think it's but - this admittedly many companies

and indications, will services set. set cancer. pricing do. plus the have or pricing $X,XXX cetera types certain for therapy would doubt I So, no PCM certain get our is certain has for therapy of The development. market the range we the the say, players same first, already for That of stratified, pricing selection - that in selection MRD cancers, monitoring It’s there other of the we in stages pricing et the kind

a impact more As question dynamic for where little on ASP, that's there here. a is as of bit

testing we what various ranging many patient be way different see what menu a that's the offered at down kind for sometimes So coming by DRAs. of of everything currently and tests prices, hundreds range a is a low have that MRD prices first, reimbursement across broad different to of of So $X,XXX pay tests for to at services. Right? from we'll to going lot is $X,XXX for

So, we're in and what the course, kind baked impact, a testing that serve cancer I’ll gets of XX% be markets same won't products combined the the understating our serve of patients access us margin the price else platform. lot guidelines, everybody - fact ASP And we that higher that's that that the million baked call are and we to in price of their more that lot we'll while the on different gross XX that those. targeting of it we're difficult cancer pricing. have reimbursement into patients within overall on XX million points, tests Frankly, our always markets those it's is two because for to the that take the we'll of And a – approved forecast. that is

where upward and of volume to then, for track kind way a accepting is the impact, price were And when to be those dual the whatever ADLT is three But it's by lift next going over saying, will - it's sure two, see that reimbursement I we're to is think on again not approval. that be kind else with hiding and years available also the one going volume us. the of The more ASP approach regulatory we'll is So, distinct getting. yes, for our exactly sure census have drive couple standard certain. the component assured the to ASP together thing

things. other. the the and or customers or committing publicly market kind FDA’s developed in way the talking as ADLT haven't different and/or demand laboratory tests, We of the one market

often sometimes are are And not. to they not tied we more pricing than

we timing In form of for it's we're nonetheless, to and [Indiscernible] a we'll be, general, at are the and And we're approval oncology these involved. given the that cancer is business. options to regulatory available. keep so, test, factors going something will it be variable But then, And yes, quarter-to-quarter. And all going all of both least of exact those exact pursuing the the all top-line on modern. driving

to what years of be ASPs our come. an expect growth high is think for kind pull a We the rate we contribute and certainly to really to upward

Got it.

Okay. Roxi, onboard. That's helpful Sean. And welcome

Thanks.

[Operator Instructions] Morgan Savant Next question is from Stanley. from Tejas

open. Your line is now

is Hey for Edmond for Tejas. This on time. guys. the Thanks

me few questions a for Just tonight.

read The that long with guys first of for do how one, sequencing? are your you them? see influencing in views light short I [Indiscernible] a announcement your term, opportunities the of and single both guess on collaboration Omniome converging for And long a what

question. Sure. appreciate No, the I

kind and we overall, can and costs around touch we as think cost how better input more I we amount the and goods, of our time looking foremost, support a globe. upon and of efficiently in services products and look forth First of at spend run lot our Ken

focusing sequencing improve the I'll that is arrangement on lower the is of the different good use - We To course particularly disease that. the to a obviously technology Pac we extent quality leave of are for of you're about than forward tests together to We to investment as the specific form a that a on use or again particularly of even doing option, to either can genomes, and your And kind options example development of with one which rare is even or benefits of patients specific cases of short efforts talking Bio in the in are go looking of partner two collaboration box read whether way the talked terms - the core not well earlier in cost. exciting more with we having to is with different of our and more not? different one pediatric the faster one the concerned that a Our the year pushing ever. so? that partly an question in the that customers factor, they where lower sequencing.

all absolutely our Nonetheless, dollars. genome How expect us. that that, that for I few honestly, more partners capabilities in combined As do at better for trial. over the are get left interesting one box, some to it's to we

We are convinced there for raw markets. sequence is demand essentially no end the to the data in applied

excited continue we're the in come. see to to really that so And trend for years –

to guys just of ballpark guardrails of $XXX would should guidance the I And in on high what any volume for think somewhere XXXk, that mean, But specifically. range? question million in to terms million? XXXk super are reaction too the we breaking REO know helpful. then, color on the you Archer will how volume your guidance. reaction we if full I Too And $XXX or terms of for assuming low we're your in not assume out about one about year, be sort business be it. Got a

Yes.

our best be level that the include our in REO that reaction, of answer approved and revenue. regulatory mix sorry REO to well FDA sort is an of driving reaction, it MRD therapy revenue guidance where as otherwise test that's – it's answer way think as products, kind we sample regulated to forward. and think oncology chemistry of oncology out well do as view kits, The best as services, different reaction, of completely comes a what Two all services, no of is as estimate it's are I or certainly LVT reporting are revenue or amp important I is, probably then, levels and to And we whether services or to oncology of indifferent. indifferent will and there think everything selection, PCM simply other different the also again, LVT we looking sample and as from our we interpretation - services. and

for you time today. Thank Understood. the

& is from Cowen question Doug Schenkel Company. Next from

open. Your now line is

Good Hey. afternoon.

three I'll me then listen. the of Let way get and out just questions my

as you you seeing from the demand the in as overall the if then, question. to can regarding delta the quarter, the variant? you access to half any So pacing are move first second the beginning physician relates first it of is, end? year, the The into to on just impacts or went talk about And how that's things

haven't admittedly relate of The second, time adjustment, chance This are Archer. to and on a had the a and very lot spend on guys accounting helpful to that does you I in your prepared remarks.

So, rather is not sure be to I payments or making plans. to Archer Clearly, that make milestone not making just anything this or payments. doesn't tell want you'd milestone tracking regarding whether us

how on you're as So leveraging decreasing into to there then that there just is we read Does increased Is we making move should change have thinking Thank And anything focus made does strategy? you profitability percentage coming Roxi if about and about are a and a sales as the years investment comment on of you. over M&A M&A? about make towards tell you as I to want sure try a kind and so, XXXX. look the to infrastructure think that that how to of comment nothing there. spend operating Roxi, relates third beyond welcome us

two do Ken Doug. of Roxi I'll and three. and could All then three. take right. then and what Thanks, Roxi two I'll do I'll one, a do. quick treatment can take and I'll tell

of than kind the as there pacing really quarter, week year. in - nothing this would unusual is pacing the nothing vacation characterize a the that, was earlier that noted there towards is of the two We end. lot just the of the folks there. about frankly I'll quarter, first quarter beginning there I story us it this - I I No strong to of a this and for may the on story overall QX drive quarter, see. come had So, have was quarter. real go Pacing then of which would looks our at soft some of had say throughout We no standard. or a But other particularly

think I side, that refrain. to story are whole is there definitely There in a access I’ll the - On the in think I still maybe where accounts going systems that's long-term. are

walking other, is a think fewer or drive around is, certainly guess, people couldn't modestly don't into going permanent that’s we - even just some certainly access. on I serve are we voicing of my our opinion boots of support demand we - and And we or the see a I customers that up industry. generate ground reduced one the that's of yet. to set some without probably a year, it I permanent – don’t that think clients kind do to we going keep picture there to role clearly, And getting for the way. away. our and a it don't are Nonetheless, continue volume with Putting we customers the way with the on it’s figure believe we unfortunately of the really can accounts,

better I reduced generally, few go concerned but yes, overly a by, little a maybe we're about. quarters I sense. we think that's nothing think might But have a general with access,

for growth let what in going impact Roxi, that, of affect adjustment question. My want Roxi think forward. is let revenues tackle not does do our material we But you whatever definitely outlook it and accounting most I'll Ken that oncology top-line On adjustment, is a the those? is way OpEx the and then business to accounting I'll and there the

right. All

of accounting it ongoing set the purpose. there contingent a as rules adjustment, especially acquisition-related relates is on liabilities, know, So, for as and accounting to liabilities stock-based you complex pretty compensation

necessary we quarter timing. we to quarter, have actually a disclosures in we and have complex patients this a the a on really need this as the pretty happens we for process. be ask close issue every and days - for we It's and and information do information based a will of this move quarter in to if and lot every allowing So coming and we assessment just quarter through timing

have. as we business the mentioned, Sean accounting any and really of this outlook So, doesn't period reflect and underlying

the as then, is point I'd not. on? What and future. that that, sales into And sufficient percentage Yes. generate we've a serving - expect to This revenue amount absolutely future bit of our Ken focus and change we're is in to quite and signaling growth see say company is a the OpEx we making of into that the about comment may we that of of was our the relative investment we going any investments patients

an investment the basis. high aggressive revenue point. a on of percentage portfolio annual that the we’re as We hit XX% expectation. have our way XX% the an is so, Well, we And sales. we probably But to again looking at think growth

will expect And the that company so, continue to we grow.

a to We just the done continue couple as will we as in percentage of last business not over have the invest of years. sales

from Ophir [Operator Gottlieb Instructions] is next Capital from Market Your question Laboratories.

is line now Your open.

have Hey Thanks guys. quarter. question. two. the I for my taking Congrats on

about talk to want the new I services First, category. data platform and

the product? have So a I is if sold? follow-up by How patient? I it it first, how a please? could is revenue And And recurring it is used

Sure.

it pharma identified So is often with not connecting already the that that or either varies. services companies patients trial. than a a certain first, have More variance with therapy

put their Sometimes that that's patient through portal. directly interaction

their research would exploration, or healthcare in. Sometimes their kind revenue support, to customer that that program in those are was like from management, it’s example, that collaboration for other healthcare use factor And clients. of workflow that that involved particular is So tech you or part providers space and and a have patient receiving experience the selling stack of to take in the testing what comes their either essentially portion you? data they part the analysis of of players, know journey cases, who other that are are with leasing services other that of we for customer-facing we services a part patient's a that our are for part

‘subscription yes, or by databases’. recurring As way for recurring, some recurring of it’s contracts access

all because it signing the patient that certainly significant the other paying. it’s behalf there of don't and What Paying what for for that portion is more - a planning looks the up are licensing high up of in a and but or Some that continued patient of on – of But that's directly, is we on and way licensing se that We a level subscription commentary. per those access. come. a customers? like it’s to se by not of have of per more a signing services recurring for of

business. can the Okay. it this margins follow-up, it, And subject, also you a be would is are don't which growth Super same? can of substantially you if go as of to not testing are is what on then, revenue core material, to piece? yet, they're than like same kind what Thanks. And that but helpful. XXXX? the X% share relevant higher back I describe any don't feels a know rates be any It starting

Yes. Yes.

some of I this would this right? delve say the think, of we se out, margin we're won't variable, – won’t of and into lot I per is we category probably I'll A - testing new it’s it offering.

being say relatively it higher charge tied cause going it's on as to still would amount that, you of of margin Some that and of is a needless a kind forward, development I going say fair forward. to revenue. be look And

today. I Ophir. think that's maybe as the sit way that put apologies, we And it I could

question part second of your The was?

don't beyond are. know you any share don’t like Yes, but XXXX, rates, can kind quite I growth of you grow

Sorry.

right. that's no, - that’s Yes,

are the this specific we for a not going for a think have I outlook guide particular specific do - we a it. or sector, don't

growing the have good the been of conversations many overall teach programs. around this growth. points line the in pharma as sponsored is and largely has programs noted above embodiment pharma We noted And a paid pharma our testing or that focused we past identification

of is we're again, is But each that certainly to And the yes, – services kind of it for look that’s all and big couple testing about off the enough kind own year-over-year. category break north what be So, patients. see growing at feel out forward. and we'll can investing versus XX% able growth - it this rates its where to excited - just we'll it's of been data together point, straightforward and going means that about excited of to about on revenue. And continuing there it's we your excited one getting

you. thank Great

Next from Benchmark question Jackson Bruce the is Company. from

questions. ask your may You

question. Thank Hi. you my for taking

mix or offering? being could by sales particular has here. of any XXXX? have international a particular is the driven of So that rough the you geography end idea it And product nicely where be any by been Do building

Yes.

those America, health the little been of basically in of minus Latin yes, by it’s we Middle are Typically, our Middle a - has East like That's East highest grows of I and businesses us are services and product sellers primarily and geography think revenue and growing and those geographies ones to the and fastest also different customers doctors kind - that and the strongest of so geographies a growing. offering and Northern are are every just the price data interest ex China. you driven can’t targeting – volume there. serve quarter Europe, advance the they of by reproductive in history are The lines cancer by reasons there, we the - and the our the cancer points bit are largest tend screening testing. for the Those be the there whole. U.S.

We – now got are excited business really now. a that now lot we've more

example health good that with therapy the of selling there. national laboratories a kits running testing is Japan - the kind into example, kind direct of For

that that product that's those We of we But tests primarily geographies are it. been excited - it's driving will and to those with push more the mix. pushing start suspect along more for right now, and geographical the mix change

Thank Okay, great. you.

Your last William question Weinstein is from from Blair. Brian

now open. is line Your

here Thanks clarify guys. the just Hey in I things. late decided of a taking just to couple to jump question.

any were you announced? from on that's away, And oncology, in sort going Just when on two specifically saw that? and player Also takeaways revenues me for better areas was like are sort anything that the talked Genosity there the of into think to disease, that it of here, that I that is specific think it what some relates performance now take in consideration, guidance kind was reproductive built guidance to into a built are about driving don't of go you excuse or were reproductive was not anything seeing – the does I exiting side? there that, you guidance on there if the the so as raise the was – one in space potential rare that but Genosity

Yes.

backwards say into there nothing - on Genosity probably anything go about kind to So of and I'll and not revenue. go nothing trying to read is

say is come we revenue BT our it, next is years, from our and couple or revenue over think practice the Genosity Now the again, growth revenue now, - I Archer revenue, bulk to from version to of MRD now going of the because is the revenue, Genosity product. revenue testing as hard PCM is right we think

provide the there. to the six story I going major U.S. see certainly to an to this question performing disease Outside either space that a over is them But think driver the pace. in to. Reproductive reproductive, months is story we years. all area contributor continue not the then answer I don't share health be in that there a about view all expect the this at we in quarter specifically looks the is going others it's take Alone to the - two or probably roughly the it some one no differently I to that's quarters year, for than It the there. least in of next us year there others. to again, to clear in is share on two or also growing next our and will outlook doubt of And probably be therein. past three one there, penetration And definitely to to area this has anyway Now year. year three kind point or continues Reproductive to faster like no are do health think margin. as definitely of in continue your major that the about we to opportunity of exit pregnancies per market two talked definitely product total suggest take at any that growing really

specific interest to not we're a so, not disease just to So, of to area And exit yes, point picking claim back that normal, Genosity COVID just just – that it period. to - true - the this no, it’s everybody. out kind and usual, going up product area we but mentioned kind of no back to wanted to thing of is business

you going about, last outlined on that Got kind we quantify the But to to that those talked your are having one, of it. you. able impact pressures And are confidence ability you business that you inflationary had have the are and kind or the those. your that offset then, an about And there kind inflation of guys other been as inflationary on detail that and to of is provide a even in if any well. you any the want wage bit to product the little that, cost hearing of on pressures here on the short-term. or we've Thank

on So, anything are Thanks. that just inflation there guys else you seeing?

you’ve been Ken, Sure. to want on else, staying any input Ken Roxi, do you or commentary on closer anybody cost that? – than our

what seen I everybody else is getting harder we've Yes. seeing to it's roles. mean, hire is I for that, think, certain

has so been And we what concern to a there associated we that adjustments the in is some landed from with aggregate of any don't But our wages. abnormalities inflation of have plan terms at, Invitae. the business see specific in

how seeing and have of your space. be we are monitoring everyone our is pressures some sight seeing And And can that’s such terms the the piece. about line to cost and revenue in that this. so, focus clear in we're inflationary question the same operating we But, mechanisms are that else proactive that clear answer of why on a moving, of so we honestly

shortages auto that impact shutting happening watching the we of industry chip like see because bigger down facilities that losing, and day the things the think I that. is

much think as a are those material having anything. I as impact of

supply that's a on and are transportation stay our ahead why in be demand our the talked and how I that's That I so marketplace. about earlier, partners the That's see focusing will two the bit it. of and little so. going base, probably we trying uncertainty to And supply on of

guys. Okay. Thank you

welcome. are You

you. Thank

Laura closing our over to ends call back session. and the That question for answer remarks. I'll turn

Thank at you to soon connecting forward look upcoming us with for We joining all conferences. today. you

today's Thank concludes call. That for you all conference participating.

You disconnect. may now